Name | Number of supported studies | Average coverage | |
---|---|---|---|
epithelial cell | 3 studies | 19% ± 1% | |
glutamatergic neuron | 3 studies | 19% ± 1% |
Insufficient scRNA-seq data for expression of ETAA1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 100% | 920.62 | 459 / 459 | 100% | 9.43 | 1114 / 1118 |
lung | 100% | 980.77 | 577 / 578 | 100% | 8.30 | 1152 / 1155 |
esophagus | 100% | 934.81 | 1445 / 1445 | 99% | 9.44 | 182 / 183 |
pancreas | 100% | 783.49 | 328 / 328 | 99% | 6.69 | 177 / 178 |
prostate | 100% | 917.36 | 245 / 245 | 99% | 6.27 | 497 / 502 |
thymus | 100% | 1160.02 | 653 / 653 | 99% | 7.87 | 598 / 605 |
ovary | 100% | 1149.89 | 180 / 180 | 99% | 6.94 | 425 / 430 |
uterus | 100% | 1240.29 | 170 / 170 | 98% | 9.14 | 450 / 459 |
brain | 98% | 433.94 | 2586 / 2642 | 100% | 7.49 | 705 / 705 |
bladder | 100% | 869.90 | 21 / 21 | 98% | 6.77 | 493 / 504 |
kidney | 100% | 726.04 | 89 / 89 | 95% | 7.70 | 858 / 901 |
adrenal gland | 100% | 1880.40 | 258 / 258 | 95% | 5.41 | 219 / 230 |
stomach | 100% | 703.11 | 358 / 359 | 95% | 5.58 | 271 / 286 |
intestine | 100% | 844.16 | 966 / 966 | 94% | 5.45 | 496 / 527 |
liver | 100% | 479.27 | 226 / 226 | 87% | 4.19 | 352 / 406 |
skin | 100% | 1143.88 | 1807 / 1809 | 84% | 5.49 | 395 / 472 |
lymph node | 0% | 0 | 0 / 0 | 100% | 6.34 | 29 / 29 |
spleen | 100% | 943.89 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 8.14 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 2.82 | 1 / 1 |
adipose | 100% | 814.15 | 1203 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 1010.16 | 1333 / 1335 | 0% | 0 | 0 / 0 |
heart | 95% | 409.90 | 821 / 861 | 0% | 0 | 0 / 0 |
muscle | 95% | 338.73 | 764 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 53% | 2.59 | 42 / 80 |
peripheral blood | 32% | 438.42 | 299 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006974 | Biological process | DNA damage response |
GO_0044818 | Biological process | mitotic G2/M transition checkpoint |
GO_0031297 | Biological process | replication fork processing |
GO_0006281 | Biological process | DNA repair |
GO_2000001 | Biological process | regulation of DNA damage checkpoint |
GO_0071902 | Biological process | positive regulation of protein serine/threonine kinase activity |
GO_0043596 | Cellular component | nuclear replication fork |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0043539 | Molecular function | protein serine/threonine kinase activator activity |
GO_0005515 | Molecular function | protein binding |
Gene name | ETAA1 |
Protein name | Ewing's tumor-associated antigen 1 (Ewing's tumor-associated antigen 16) ETAA1 activator of ATR kinase |
Synonyms | ETAA16 |
Description | FUNCTION: Replication stress response protein that accumulates at DNA damage sites and promotes replication fork progression and integrity . Recruited to stalled replication forks via interaction with the RPA complex and directly stimulates ATR kinase activity independently of TOPBP1 . Probably only regulates a subset of ATR targets . . |
Accessions | A0A2R8Y6Y8 ENST00000272342.6 ENST00000644028.1 Q9NY74 A0A2R8YEV8 ENST00000645739.1 A0A2R8Y7B6 ENST00000462772.2 |